MOLECULIN BIOTECH INC COM USD0.001(POST REV SPLIT

As of June 30, 2026, MOLECULIN BIOTECH INC COM USD0.001(POST REV SPLIT carries a market capitalization of 376.30M, placing it among publicly traded companies globally. Its enterprise value stands at 369.33M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

MOLECULIN BIOTECH INC COM USD0.001(POST REV SPLIT's next confirmed earnings release is scheduled for November 9, 2026.

As of June 30, 2026, MOLECULIN BIOTECH INC COM USD0.001(POST REV SPLIT has 7.10M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, MOLECULIN BIOTECH INC COM USD0.001(POST REV SPLIT maintains a current ratio of 0.94, meaning it holds 0.9x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026. Return on assets (ROA) is negative at -142.11, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 17.00, a quick read on workforce productivity versus industry peers.

As of the close on October 19, 2026, MOLECULIN BIOTECH INC COM USD0.001(POST REV SPLIT's stock has declined approximately 97.88% over the past 52 weeks. The 50-day moving average sits at 0.58, while the 200-day moving average is 2.23.

Over the twelve months ended June 30, 2026, MOLECULIN BIOTECH INC COM USD0.001(POST REV SPLIT generated - - in revenue and converted that into -30.33M in net income, yielding earnings per share of -10.59. EBITDA reached -28.83M, while operating income came in at -28.87M.

As of June 30, 2026, MOLECULIN BIOTECH INC COM USD0.001(POST REV SPLIT holds 7.26M in cash and equivalents against 292,000.00 in total debt, resulting in a net debt position of -7.26M. Total book value stands at 11.59M, with working capital of -590,000.00 providing operational flexibility.

MOLECULIN BIOTECH INC COM USD0.001(POST REV SPLIT produced -25.36M in operating cash flow over the twelve months ended June 30, 2026. After subtracting - - in capital expenditures, free cash flow totaled -25.36M - equivalent to -8.85 per share.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -16.70: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -6.67, meaning MOLECULIN BIOTECH INC COM USD0.001(POST REV SPLIT raised more capital through share issuance and new debt than it returned via dividends and buybacks.

MOLECULIN BIOTECH INC COM USD0.001(POST REV SPLIT's most recent stock split took place on October 20, 2026 with a 20:1 split ratio.

As of June 30, 2026, MOLECULIN BIOTECH INC COM USD0.001(POST REV SPLIT has an Altman Z-Score of -17.79, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.